Data Sheet (Cat.No.T16937)



ST 2825


Chemical Properties

CAS No.: 894787-30-5

Formula: C27H28Cl2N4O5S

Molecular Weight: 591.51
Appearance: N/A

Storage: 0-4°C for short term (days to weeks), or -20°C for long term (months).



Biological Description

Description	ST 2825 is a specific MyD88 dimerization inhibitor. ST2825 inhibition of IL-1 β -mediated activation of NF- κ B transcriptional activity.
Targets(IC ₅₀)	MyD88: None
In vitro	ST2825 blocks IL-1R/TLR signaling by interfering with MyD88 homodimerization. ST2825 inhibits this interaction in a concentration-dependent manner with \sim 40% inhibition of dimerization at ST2825 (5 μ M) and 80% inhibition at ST2825 (10 μ M) [1].
In vivo	ST2825 dose-dependently inhibits IL-1 β -induced production of IL-6 in treated mice after oral administration. ST2825 exerts a significant inhibition of IL-1 β -stimulated production of IL-6 at 100 and 200 mg/kg. The animals are administered orally with the appropriate vehicles or ST2825 at doses ranging from 50 to 200 mg/kg, 5 min prior to i.p. injection with 20 μ g/kg IL-1 β [1].

Solubility Information

Solubility	DMSO: 100 mg/mL (169.06 mM) (< 1 mg/ml refers to the product slightly soluble or insoluble)
	(< 1 mg/mirrelets to the product slightly soluble of insoluble)

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.691 mL	8.453 mL	16.906 mL
5 mM	0.338 mL	1.691 mL	3.381 mL
10 mM	0.169 mL	0.845 mL	1.691 mL
50 mM	0.034 mL	0.169 mL	0.338 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. The storage conditions and period of the stock solution: - $80 \,^{\circ}$ C for 6 months; - $20 \,^{\circ}$ C for 1 month. Please use it as soon as possible.

Page 1 of 2 www.targetmol.com

Reference

- 1. Loiarro M, et al. Pivotal advance: inhibition of MyD88 dimerization and recruitment of IRAK1 and IRAK4 by a novel peptidomimetic compound. J Leukoc Biol. 2007 Oct;82(4):801-10.
- 2. Fantò N, et al. Design, Synthesis, and In Vitro Activity of Peptidomimetic Inhibitors of Myeloid Differentiation Factor 88. J Med Chem. 2008 Mar 13;51(5):1189-202.
- 3. Van Tassell BW, et al. Pharmacologic Inhibition of Myeloid Differentiation Factor 88 (MyD88) Prevents Left Ventricular Dilation and Hypertrophy After Experimental Acute Myocardial Infarction in the Mouse. J Cardiovasc Pharmacol. 2010 Apr;55(4):385-90.
- 4. Zhang HS, et al. Inhibition of myeloid differentiation factor 88(MyD88) by ST2825 provides neuroprotection after experimental traumatic brain injury in mice. Brain Res. 2016 Jul 15;1643:130-9.
- 5. Wang N, et al. Myeloid differentiation factor 88 is up-regulated in epileptic brain and contributes to experimental seizures in rats. Exp Neurol. 2017 Sep;295:23-35.
- 6. Brad Griesenauer, et al. ST2/MYD88 signaling is a therapeutic target alleviating murine acute graft-versus-host disease sparing T regulatory cell function. Indiana University. May 2018.

Inhibitors · Natural Compounds · Compound Libraries

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use.

Tel:781-999-4286 E-mail:info@targetmol.com Address:36 Washington Street, Wellesley Hills, MA 02481

Page 2 of 2 www.targetmol.com